Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00863941 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting Conditions
A Phase 1 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00863941 is a Phase 1 study that has completed, run by Actavis. The registered enrollment target is 28 participants.
The verdict
NCT00863941, a Phase 1 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
To compare the rate and extent of absorption of Abrika Bupropion 150 mg XL Tablet to that of Wellbutrin XL® 150 mg Tablet after a single, one-tablet dose in fasted subjects.
Interventions
- DRUG Abrika Bupropion 150 mg XL Tablet, single dose
- DRUG Wellbutrin XL® 150 mg Tablet, single dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2004-06 |
| Est. Completion | 2004-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00863941
The ClinicalTrials.gov registry entry for NCT00863941 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Abrika Bupropion 150 mg XL Tablet, single dose is the first listed.
NCT00863941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00863941 about?
NCT00863941 is a clinical study titled "A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting Conditions". To compare the rate and extent of absorption of Abrika Bupropion 150 mg XL Tablet to that of Wellbutrin XL® 150 mg Tablet after a single, one-tablet dose in fasted subjects.
What is the current status of trial NCT00863941?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2004-06. Estimated completion is 2004-07.
What interventions are being tested in trial NCT00863941?
The interventions under investigation include: Abrika Bupropion 150 mg XL Tablet, single dose (DRUG), Wellbutrin XL® 150 mg Tablet, single dose (DRUG).
Who is sponsoring clinical trial NCT00863941?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.